OMO-103 + gemcitabine + nab-paclitaxel

OMO-103 + gemcitabine + nab-paclitaxel is an investigational combination regimen targeting advanced solid tumors, with active research in metastatic pancreatic cancer and advanced osteosarcoma. OMO-103, developed by Peptomyc, is a cell-penetrating mini-protein that directly inhibits the MYC oncoprotein, a master regulator frequently deregulated in cancer. OMO-103 is the first direct MYC inhibitor to enter clinical trials, showing target engagement and manageable safety[5][3][1][7]. Gemcitabine is a nucleoside analog chemotherapy agent that inhibits DNA synthesis, leading to apoptosis of rapidly proliferating cancer cells. Nab-paclitaxel is a formulation of paclitaxel bound to albumin nanoparticles, enabling improved tumor delivery and a reduced risk of solvent-related toxicity; its action mechanism is inhibition of microtubule disassembly in mitotic cells[2][4][6][8]. The combination of gemcitabine and nab-paclitaxel is established in metastatic pancreatic cancer and demonstrates improved overall survival, progression-free survival, and tumor response rates versus gemcitabine alone. The triple combination aims to enhance efficacy through synergistic targeting: MYC inhibition (OMO-103), DNA synthesis blockade (gemcitabine), and mitotic inhibition (nab-paclitaxel).

Other names

Omomyc-based MYC inhibitor (OMO-103)gemcitabinealbumin-bound paclitaxel (nab-paclitaxel)Abraxane (nab-paclitaxel)